In Vitro Synergy and Selection of Resistance by Fluoroquinolones Plus Amikacin or β-Lactams Against Extended-Spectrum β-Lactamase-Producing Escherichia coli

References

• Fluit AC, Schmitz FJ, Verhoef J. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001; 20: 188–191.
   PubMed Web of Science ®Google Scholar
• Jones RN, Pfaller MA, The MYSTIC Study Group (Europe). Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708–712.
   Google Scholar
• Arpin C, Dubois V, Coulange L et al. Extended spec-trum beta-lactamase-producing Enterobacteriaceae in commu-nity and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506–3514.
   Google Scholar
• Pagani L, Dell'Amico E, Migliavacca R. Multiple CTX-M-Type extended -spectrum 13-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northern Italy. J Clin Microbiol 2003; 41: 4264-4269.
   Google Scholar
• Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum 13-lactamases among Enterobacteriaceae: an Italian survey. Int J Antimicrob Agents 2002; 19: 213–217.
   PubMed Web of Science ®Google Scholar
• Winkour PI, Canton R, Casellas R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characteri-zation of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001: 32 (suppl 2): S94-103.
   Google Scholar
• Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D, Catal C, And-Kucuker M, Ang O. Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004; 10: 72–75.
   PubMed Web of Science ®Google Scholar
• Unal S, Masterton R, Goossens H. Bacteraemia in Europe-antimicrobial susceptibility data from the MYSTIC sur-veillance programme. Int J Antimicrob Agents 2004; 23: 155–163.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988; 1: 139–156.
   PubMedGoogle Scholar
• Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA. In vitro synergy studies using aztreonam and fluoroquinolone combinations againstsix species of Gram negative bacilli. Chemotherapy 2003; 49: 44–48.
   PubMed Web of Science ®Google Scholar
• Gradelski E, Kolek B, Bonner DP, Valera L, Minassian B, Fung-Tomc J. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001; 17: 103–107.
   PubMed Web of Science ®Google Scholar
• Clark CL, Jacobs MR, Appelbaum PC. Activities of cli-nafloxacin alone and in combination with other compounds, against 45 Gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob Agents Chemother 1999; 43: 2295-2298.
   Google Scholar
• Gimeno C, Borja J, Navarro D, Valdes L, Gracia-Barbal J, Garcia de Lomas J. In vitro interaction between ofloxacin and cefotaxime against Gram-positive and Gram-negative bac-teria involved in serious infections. Chemotherapy 1998; 44: 94–98.
   Google Scholar
• Michêa Hamzehpour M, Kahr A, Pechère JC. In vitro stepwise selection of resistance to quinolones, I3-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22 (suppl 2): S105-110.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M 100-S 11. Villanova, NCCLS, 2001.
   Google Scholar
• European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): EUCAST Definitive Document E. Def 1.2. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-508.
   Google Scholar
• Bajaksouzian S, VisaIli MA, Jacobs MR, Appelbaum PC. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997; 41: 1073–1076.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655–662.
   Google Scholar
• Molstad S. Reduction in antibiotic prescribing for respi-ratory tract infections is needed! Scan J Prim Health Care 2003; 21: 196–198.
   Google Scholar
• Lan CK, Hsueh PR, Wong WW et al. Association of antibiotic utilization measures and reduced incidence of infec-tions with extended-spectrum beta-lactamase-producing organ-isms. J Microbiol Immunol Infect 2003; 36: 182–186.
   PubMedGoogle Scholar
• Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27 (Suppl 2): S24–28.
   PubMed Web of Science ®Google Scholar
• Chan WC, Li RC, Ling JM, Cheng AF, Schentag JJ. Markedly different rates and resistance profiles exhibited by seven commonly used and newer Alactams on the selection of resistant variant of Enterobacter cloacae. J Antimicrob Chemother 1999; 43: 55–60.
   PubMed Web of Science ®Google Scholar